Andrew T. Kuykendall

Hematology Oncology | Internal Medicine
12902 Usf Magnolia Dr
Tampa, FL 33612

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 122 publications

Hematopoietic mosaic chromosomal alterations are pleiotropic drivers of inflammaging, multimorbidity, and mortality.

Hematopoietic mosaic chromosomal alterations are pleiotropic drivers of inflammaging, multimorbidity, and mortality.

Journal: medRxiv : the preprint server for health sciences
Published: July 10, 2026

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: July 09, 2026

Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia.

Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia.

Journal: Journal of the American Heart Association
Published: May 06, 2026

Risk of Thromboembolic Events in Patients With Polycythemia Vera: A Real-World Observational Study.

Risk of Thromboembolic Events in Patients With Polycythemia Vera: A Real-World Observational Study.

Journal: Clinical lymphoma, myeloma & leukemia
Published: April 03, 2026

Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014-2024).

Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014-2024).

Journal: Annals of hematology
Published: April 02, 2026

Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach.

Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach.

Journal: Leukemia
Published: March 20, 2026

Clinical features and outcomes of MPN with concurrent MPL and JAK2/CALR Mutations.

Clinical features and outcomes of MPN with concurrent MPL and JAK2/CALR Mutations.

Journal: Blood neoplasia
Published: March 09, 2026

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.

Journal: Future oncology (London, England)
Published: March 07, 2026

Limited Prognostic Value of ELN Classification and Relevance of Molecular Ontogeny in Acute Myeloid Leukemia post Myeloproliferative Neoplasms: A Retrospective Multicenter Study.

Limited Prognostic Value of ELN Classification and Relevance of Molecular Ontogeny in Acute Myeloid Leukemia post Myeloproliferative Neoplasms: A Retrospective Multicenter Study.

Journal: Acta haematologica
Published: February 27, 2026

Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survival.

Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survival.

Journal: Leukemia & lymphoma
Published: February 27, 2026

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

Journal: Cancer
Published: February 19, 2026

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

Journal: HemaSphere
Published: October 21, 2025
Showing 1-12 of 122

Last Updated: 09/26/2026